Harvard John A. Paulson School of Engineering and Applied Sciences, 29 Oxford Street, Cambridge, MA, 02138, USA.
Center for Quantitative Health, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114, USA.
Transl Psychiatry. 2020 Feb 6;10(1):60. doi: 10.1038/s41398-020-0716-y.
Antidepressants exhibit similar efficacy, but varying tolerability, in randomized controlled trials. Predicting tolerability in real-world clinical populations may facilitate personalization of treatment and maximize adherence. This retrospective longitudinal cohort study aimed to determine the extent to which incorporating patient history from electronic health records improved prediction of unplanned treatment discontinuation at index antidepressant prescription. Clinical data were analyzed from individuals from health networks affiliated with two large academic medical centers between March 1, 2008 and December 31, 2014. In total, the study cohorts included 51,683 patients with at least one International Classification of Diseases diagnostic code for major depressive disorder or depressive disorder not otherwise specified who initiated antidepressant treatment. Among 70,121 total medication changes, 16,665 (23.77%) of them were followed by failure to return; maximum risk was observed with paroxetine (27.71% discontinuation), and minimum with venlafaxine (20.78% discontinuation); Mantel-Haenzel χ (8 df) = 126.44, p = 1.54e-23 <1e-6. Models incorporating diagnostic and procedure codes and medication prescriptions improved per-medication Areas Under the Curve (AUCs) to a mean of 0.69 [0.64-0.73] (ranging from 0.62 for paroxetine to 0.80 for escitalopram), with similar performance in the second, replication health system. Machine learning applied to coded electronic health records facilitates identification of individuals at high-risk for treatment dropout following change in antidepressant medication. Such methods may assist primary care physicians and psychiatrists in the clinic to personalize antidepressant treatment on the basis not solely of efficacy, but of tolerability.
抗抑郁药在随机对照试验中表现出相似的疗效,但耐受性不同。预测真实世界临床人群的耐受性可能有助于治疗的个体化,并最大限度地提高依从性。这项回顾性纵向队列研究旨在确定在抗抑郁药处方时纳入电子健康记录中的患者病史在多大程度上可以提高对计划外治疗中断的预测。临床数据来自于 2008 年 3 月 1 日至 2014 年 12 月 31 日期间隶属于两个大型学术医疗中心的健康网络的个人。共有 51683 名至少有一个国际疾病分类诊断代码为重度抑郁症或未特指的抑郁障碍的患者开始接受抗抑郁治疗。在总共 70121 次药物变化中,有 16665 次(23.77%)未再返回;帕罗西汀(27.71%停药)的最大风险,文拉法辛(20.78%停药)的最小风险;Mantel-Haenzel χ(8df)=126.44,p=1.54e-23<1e-6。纳入诊断和程序代码以及药物处方的模型提高了每种药物的曲线下面积(AUC),平均为 0.69[0.64-0.73](范围从帕罗西汀的 0.62 到依地普仑的 0.80),在第二个复制的健康系统中表现相似。应用于编码电子健康记录的机器学习有助于识别在改变抗抑郁药物后治疗中断风险高的个体。这些方法可以帮助初级保健医生和精神科医生在诊所中根据疗效以外的因素,如耐受性,个性化抗抑郁治疗。